Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary

Abstract

The approval and adoption of biosimilar products are essential to contain increasing healthcare costs and provide more affordable choices for patients. Despite steady progress in the number of the US Food and Drug Administration (FDA) biosimilar approvals over the years, biosimilar adoption in the United States has been slow and gradual, largely driven by payers rather than clinicians. In order to better understand the barriers to biosimilar adoption in the clinic,

Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study

“…42, 43 A knowledge gap among providers may be another issue, as familiarity and terminology could play a role in choosing the agent. 44, 45 It should be emphasized that projecting savings associated with biosimilars entrance on the United States market depends on changing regulatory structure and insurer's calculations. [46][47][48] Policy changes toward extending access to innovative treatment should also consider patient--level factors, with potential preference for oral or subcutaneous formulations.…”

Clinical Traditional Chinese Medicine Research in Hospitals and Its Clinical Value Analysis

“…They reduced the incidence of medication errors in pharmacies through detailed data analysis and process optimization [3]. Shubows et al explored the application and challenges of biologically similar drugs in clinical practice from different perspectives, and they believed that clinical pharmacology played an important role in the evaluation, selection, and monitoring of biologically similar drugs [4]. Le L M et al conducted an updated systematic evaluation and meta-analysis on the impact of pharmacist involvement on immunization rates and other outcomes.…”

Advancing Innovations in Biosimilars

“…Three articles in this issue discuss efforts needed to improve biosimilar uptake and adoption. Shubow et al 16 . describe the perspectives of four leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology, which was informed by their clinical experience and real‐world data on clinical use of biosimilars globally.…”

“…Three articles in this issue discuss efforts needed to improve biosimilar uptake and adoption. Shubow et al 16 perspectives of four leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology, which was informed by their clinical experience and real-world data on clinical use of biosimilars globally. They call for educational efforts to highlight the rigor of studies that support the of biosimilarsincluding the clinical pharmacology studies-and the benefits of biosimilars, thereby increasing the awareness, building the confidence, and ultimately improving biosimilar acceptance.…”